• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

Improving Lives

Focusing on the development and commercialisation of neurological solutions

Learn More

ASX:NTI

Exclusive worldwide licence

Extensive preclinical studies completed

Neurotech’s Mente device and therapy

Paediatric Focus

Potential for NTI164 to treat neurological disorders

PCT Patents lodged

Neurotech is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life. NTI’s current focus is their world-first clinical study utilising NTI164 in the treatment for paediatric Autism Spectrum Disorder (ASD).

 The Company is also focused on commercialising Mente, the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

Learn More

Bioshares Report
Now Available

Neurotech International (NTI: $0.071) has released the results from its Phase II study in children with moderate autism spectrum disorder (ASD). The study involved 14 children who were treated with lead drug candidate, NTI164.

Read Full Report

Latest Announcements

View All

Latest News

  • Company Presentation, NWR Communications

    NWR Virtual Healthcare Conference Presentation: Neurotech International Investor Presentation

    22 Mar 2023
  • Company Presentation

    Neurotech International: 52 Week Phase I/II Autism Clinical Trial Data Presentation with Dr Thomas Duthy

    17 Mar 2023
  • Neurotech International: Quarterly Investor Conference Call with Dr Thomas Duthy

    30 Jan 2023
  • SBS News

    SBS News: New study examines medicinal cannabis treatment for people with autism

    19 Nov 2022

View All

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1679466087anoit1679466087anret1679466087nihce1679466087torue1679466087n@ofn1679466087i1679466087

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus